Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Neeraj Sardana

Gastroenterology Catonsville, MD Medical Doctor

NPI 1679783021 CMS profile 166541

700 Geipe Rd, Suite 230, Catonsville, MD 21228

Open in the dashboard

General payments

$4,905

248 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Neeraj Sardana of Catonsville, MD is reported in the CMS Open Payments database as having received $4,905 across 248 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,065 45
2024 General $1,228 49
2023 General $764 38
2022 General $332 19
2021 General $561 33
2020 General $243 11
2019 General $712 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Neeraj Sardana
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Neeraj Sardana were reported at $1,065. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Neeraj Sardana Gastroenterology median Middle half National median
2019 $712 $417 $126–$1,100 $163
2020 $243 $224 $74–$624 $114
2021 $561 $352 $106–$1,054 $132
2022 $332 $448 $129–$1,270 $149
2023 $764 $533 $150–$1,390 $160
2024 $1,228 $605 $160–$1,606 $164
2025 $1,065 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $836 45 payments
  2. Janssen Biotech, Inc. $513 24 payments
  3. AbbVie, Inc. $374 19 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $345 18 payments
  5. Pfizer Inc. $328 15 payments
  6. QOL Medical, LLC $218 9 payments
  7. Intercept Pharmaceuticals, Inc. $198 8 payments
  8. Ironwood Pharmaceuticals, Inc $167 10 payments
  9. Aimmune Therapeutics, Inc. $152 6 payments
  10. Genzyme Corporation $139 5 payments
  11. Other $1,634 89 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,905 248 payments
Products named General payments · program years 2019–2025
  1. ENTYVIO $530 20 payments
  2. STELARA $345 17 payments
  3. XIFAXAN $305 15 payments
  4. XELJANZ $260 11 payments
  5. LINZESS $192 11 payments
  6. CREON $190 10 payments
  7. OCALIVA $177 7 payments
  8. ZENPEP $171 9 payments
  9. VELSIPITY $170 5 payments
  10. TREMFYA $168 7 payments
  11. Other $2,984 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

570

Median for Gastroenterology: 569

Drug cost

$138,830

Median for Gastroenterology: $104,976

Branded share of claims

43.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 23 $81,048
Linzess Linaclotide Brand 30 $29,782
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 151 $8,342
Movantik Naloxegol Oxalate Brand 16 $7,316
Mesalamine Generic 11 $6,583
Ursodiol Generic 13 $1,214
Pantoprazole Sodium Generic 128 $1,199
Hydrocortisone Generic 18 $697
Ondansetron Odt Ondansetron Brand 28 $606
Omeprazole Generic 43 $503

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$184,617

Of which drugs: $78,943

Medicare patients

471

Average age 73

Services billed

5,292

252 women, 219 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 42%
Ischemic heart disease 28%
Chronic kidney disease 27%
Depression 26%
Cancer 21%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $189
$189 — —
STELARA
  • Janssen Biotech, Inc. $129
$129 — —
OCALIVA
  • INTERCEPT PHARMACEUTICALS, INC. $102
$102 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $77
$77 — —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $64
$64 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

248 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record